Constellation Pharmaceuticals Inc (NASDAQ:CNST) – Research analysts at Jefferies Financial Group issued their Q3 2019 earnings per share estimates for shares of Constellation Pharmaceuticals in a report issued on Tuesday, March 19th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will earn ($0.80) per share for the quarter. Jefferies Financial Group also issued estimates for Constellation Pharmaceuticals’ Q4 2019 earnings at ($0.64) EPS.

Several other equities analysts have also commented on CNST. HC Wainwright started coverage on Constellation Pharmaceuticals in a research report on Thursday, December 20th. They set a “buy” rating and a $18.00 price objective on the stock. Zacks Investment Research upgraded Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a research report on Wednesday, January 9th. ValuEngine lowered Constellation Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Finally, Robert W. Baird started coverage on Constellation Pharmaceuticals in a research report on Monday, January 28th. They set an “outperform” rating and a $17.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $17.25.

Shares of Constellation Pharmaceuticals stock opened at $11.49 on Thursday. The stock has a market cap of $294.18 million and a PE ratio of -2.21. Constellation Pharmaceuticals has a 12 month low of $4.01 and a 12 month high of $12.45.

Constellation Pharmaceuticals (NASDAQ:CNST) last announced its earnings results on Thursday, March 14th. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.03).

Several institutional investors have recently made changes to their positions in CNST. Geode Capital Management LLC increased its position in shares of Constellation Pharmaceuticals by 16.9% during the 4th quarter. Geode Capital Management LLC now owns 13,735 shares of the company’s stock valued at $55,000 after purchasing an additional 1,987 shares during the last quarter. Northern Trust Corp grew its position in Constellation Pharmaceuticals by 12.4% during the 4th quarter. Northern Trust Corp now owns 51,008 shares of the company’s stock worth $204,000 after acquiring an additional 5,624 shares during the last quarter. Sphera Funds Management LTD. bought a new position in Constellation Pharmaceuticals during the 4th quarter worth approximately $281,000. Dean Capital Investments Management LLC bought a new position in Constellation Pharmaceuticals during the 3rd quarter worth approximately $351,000. Finally, VHCP Management III LLC bought a new position in Constellation Pharmaceuticals during the 3rd quarter worth approximately $449,000. Hedge funds and other institutional investors own 60.05% of the company’s stock.

Constellation Pharmaceuticals Company Profile

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

Read More: Options Trading

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.